![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, August 23, 2022 8:20:04 AM
Jackson Center, Pennsylvania--(Newsfile Corp. - August 23, 2022) -
Halberd Corporation (OTC Pink: HALB) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death-1) is a T-Cell protein which can be used by tumor cells to fool the body's immune system into allowing the tumor to grow1. Halberd's extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and allow the body's innate immune system to attack and eliminate the cancer tumor. This is the main objective of drug-based immunotherapy treatments which are being tested by pharmaceutical companies. Halberd's patented extracorporeal removal process is designed to restore healthy PD-1 levels in hours as opposed to days or months as with drug treatments.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist, stated, "Drug companies have been treating thousands of patients throughout the world with anti-PD-1 ability drugs which are showing promising results. The results to date give us a high degree of confidence that we are on the right track in the fight against cancer through the precise control of PD-1 levels. The ability to exactly and precisely control the cancer target antigens is what I like to call "God's method of curing cancer". Simply put, I strongly believe, based on numerous medical articles, that the ability to very precisely control the concentration of cancer target antigens (PD-1, CTLA-4, , IL-6, TNF-alpha, etc.) will be the key to finally curing cancer, and beating it at any stage. The Halberd in-vitro experimentation, under our direction at our partner universities, is the first very primitive, yet successful, experimentation showing that this proof-of-concept is entirely possible."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We are encouraged by these initial results in our in-vitro testing using human blood serum. Our unique, and, in fact, unprecedented ability to fine tune the process and precisely control PD-1 and other antigens, is critically important given that many of the antigens which we have successfully eradicated in-vitro are important to the body, but which have reached dangerously excessive levels. PD-1 cells can be manipulated by cancer cells to allow cancer cells to multiply unchecked. We are confident that our methodology of eliminating disease at the source, in this case by removing excess PD-1 cells from the blood can lead to lower cost, safer and yet more effective cancer treatments, with few if any dangerous side effects. We see this as a revolutionary step in the developing field of immunotherapy."
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
https://www.newsfilecorp.com/release/134539
Anti-PD-1: A Novel Immunotherapy
A key factor in the development of melanoma is the ability of cancerous cells to evade the body’s natural defenses against foreign and diseased cells. Johns Hopkins scientists are studying how to educate the immune system to recognize and kill melanoma cells in a variety of ways, including arming immune T cells with specific capabilities in detecting melanoma.
Researchers at Johns Hopkins Kimmel Cancer Center are leading the way in developing novel immunotherapies called anti-PD-1 and anti-PD-L1 for people with advanced melanomas. The therapies aim not to kill cancer cells directly but to block a pathway that shields tumor cells from immune system components able and poised to fight cancer.
https://www.hopkinsmedicine.org/kimmel_cancer_center/cancers_we_treat/melanoma/_archive_me/anti_pd_1.html
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM